S&P 500
7,588.60
+0.51%
Dow Jones
52,758.90
+0.47%
Nasdaq 100
29,885.70
+0.46%
Russell 2000
2,982.51
-0.27%
FTSE 100
10,543.60
+0.61%
Nikkei 225
69,317.20
+0.42%

Investing

Pharmaceutical Companies Sign $180 Million Deal (ENDP, BDSI)

Photo of Paul Ausick
By Paul Ausick Published

Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP has signed a deal with BioDelivery Sciences International Inc. (NASDAQ: BDSI) under which Endo will license and pay royalties on a pain treatment drug and delivery system developed by BioDelivery. The agreement will be worth up to $180 million to BioDelivery.

The deal includes an upfront payment of $30 million to BioDelivery and a further $150 million as certain milestones are reached. The licensed drug, known as BEMA Buprenorphine, is currently in Phase 3 trials for the treatment of moderate to severe chronic pain.

Contact [email protected] for any questions or corrections.

Follow 24/7 Wall St. on Google
Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Chris Lange |

How an FDA Approval Changes the Game for Endo and BioDelivery Sciences

Endo International and BioDelivery Sciences have announced that the U.S. Food and Drug Administration (FDA) approved their long-term opioid treatment,…

6 BioPharma Movers That Cannot Be Ignored
Chris Lange |

6 BioPharma Movers That Cannot Be Ignored

Last week, a few biotech companies made absolutely massive runs, and some had serious falls.

Endo Sells Back Its Rights to Opioid Drug and Moves to Restructure
Chris Lange |

Endo Sells Back Its Rights to Opioid Drug and Moves to Restructure

Shares of Endo International saw a handy gain on Thursday after the company announced that it sold back its rights…

Chris Lange |

5 Big FDA Decisions Expected in October

24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of October and…

Jon C. Ogg |

Piper Jaffray’s Seven Biotech Stocks to Buy With Huge Potential Upside

Once again, the analysts at Piper Jaffray are conducting extensive management meetings with the companies they cover. Here are the…

Trey Thoelcke |

Teva Acquisition Machine Gears Up: Who Is the Next Target?

Teva Pharmaceutical resume a deal-making strategy that made it one of the most acquisitive drug companies of the past decade.…

RBC Out With Top Specialty Pharmaceutical Stocks to Buy for 2016
Lee Jackson |

RBC Out With Top Specialty Pharmaceutical Stocks to Buy for 2016

These specialty pharmaceutical stocks have tremendous upside potential for 2016 and could be offering investors outstanding entry points at current…

Ocular Therapeutics Sinks Following Secondary Offering
Chris Lange |

Ocular Therapeutics Sinks Following Secondary Offering

Ocular Therapeutix, Inc. (NASDAQ: OCUL) saw its shares take a dive on Tuesday after the company announced the pricing of…

Chris Lange |

5 Big Biotechs Not Keeping Up at All With Hot Biotech Sector in 2015

The health care sector and biotech in particular have been on fire so far in 2015, but some biotech stocks…

Top Gaining Stocks

Meta
META • Vol: 40,739,449
CarMax
KMX • Vol: 2,287,986
Weyerhaeuser
WY • Vol: 6,523,220
SBA Communications
SBAC • Vol: 1,443,798
NVIDIA
NVDA • Vol: 148,108,579

Top Losing Stocks

Moderna
MRNA • Vol: 9,168,083
Coterra Energy
CTRA • Vol: 73,319,495
CrowdStrike
CRWD • Vol: 9,260,403
Datadog
DDOG • Vol: 5,133,819
EPAM Systems
EPAM • Vol: 1,164,560